Stock listing
LSE:GENF Genflow Biosciences PLC Share Price
Home listing (LSE) of Genflow Biosciences PLC
Follow Genflow Biosciences PLC into a list and get an email when it puts out news.
Share price · LSE:GENF
1.55p GBX (pence) -0.05 (-3.1%)
Close on Nov 20, 2026
- Day range
- 1.50p – 1.65p GBX (pence)Nov 20, 2026
- Volume
- 1.06M sharesNov 20, 2026
- Market cap
- £9.22M GBPAt the close on Nov 20, 2026 · price × 594.5M shares outstanding
- 52-week range
- 1.21p – 3.12p GBX (pence)Lowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- £42,314 GBPMedian day 925,096 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| LSE:GENF · Home | 1.55p GBX (pence) | -0.05 (-3.1%) | 1,059,086 | 1.60p | 1.65p | 1.50p | 1.60p | Close on Nov 20, 2026 |
| OTC:GENFF | $0.028 USD | -0.002 (-6.7%) | 200 | $0.028 | $0.028 | $0.028 | $0.030 | Close on Nov 20, 2026 |
| Frankfurt:WQ5 | €0.018 EUR | -0.001 (-5.4%) | — | €0.015 | €0.019 | €0.015 | €0.019 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · LSE:GENF · GBX (pence), adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 1.55p | -0.05 | -3.1% | 1.60p | 1.65p | 1.50p | 1,059,086 | |
| 1.60p | -0.025 | -1.5% | 1.607p | 1.636p | 1.55p | 634,608 | |
| 1.625p | -0.025 | -1.5% | 1.617p | 1.65p | 1.615p | 275,127 | |
| 1.65p | 0.00 | 0.0% | 1.65p | 1.69p | 1.65p | 65,607 | |
| 1.65p | 0.00 | 0.0% | 1.659p | 1.70p | 1.60p | 62,797 | |
| 1.65p | 0.00 | 0.0% | 1.605p | 1.735p | 1.60p | 471,154 | |
| 1.65p | +0.025 | +1.5% | 1.65p | 1.68p | 1.605p | 432,505 | |
| 1.625p | -0.11 | -6.3% | 1.65p | 1.65p | 1.60p | 730,762 | |
| 1.735p | +0.01 | +0.6% | 1.785p | 1.785p | 1.61p | 2,127,555 | |
| 1.725p | -0.10 | -5.5% | 1.80p | 1.80p | 1.71p | 1,189,771 | |
| 1.825p | 0.00 | 0.0% | 1.825p | 1.825p | 1.757p | 195,715 | |
| 1.825p | +0.025 | +1.4% | 1.829p | 1.829p | 1.756p | 499,497 | |
| 1.80p | -0.025 | -1.4% | 1.75p | 1.90p | 1.75p | 349,897 | |
| 1.825p | 0.00 | 0.0% | 1.843p | 1.94p | 1.75p | 7,235 | |
| 1.825p | 0.00 | 0.0% | 1.825p | 1.843p | 1.825p | 559 | |
| 1.825p | -0.075 | -3.9% | 1.843p | 1.94p | 1.75p | 85,472 | |
| 1.90p | +0.075 | +4.1% | 1.873p | 1.90p | 1.762p | 432,333 | |
| 1.825p | -0.075 | -3.9% | 1.761p | 1.94p | 1.75p | 297,967 | |
| 1.90p | +0.075 | +4.1% | 1.756p | 1.90p | 1.75p | 582,601 | |
| 1.825p | +0.075 | +4.3% | 1.775p | 1.852p | 1.70p | 2,644,212 | |
| 1.75p | 0.00 | 0.0% | 1.75p | 1.835p | 1.70p | 82,308 | |
| 1.75p | 0.00 | 0.0% | 1.75p | 1.80p | 1.713p | 32,114 | |
| 1.75p | 0.00 | 0.0% | 1.75p | 1.835p | 1.712p | 699,817 | |
| 1.75p | 0.00 | 0.0% | 1.75p | 1.835p | 1.712p | 148,540 | |
| 1.75p | -0.05 | -2.8% | 1.80p | 1.85p | 1.72p | 3,061,801 | |
| 1.80p | 0.00 | 0.0% | 1.80p | 1.90p | 1.727p | 591,879 | |
| 1.80p | 0.00 | 0.0% | 1.80p | 1.90p | 1.70p | 925,096 | |
| 1.80p | 0.00 | 0.0% | 1.80p | 1.93p | 1.70p | 801,698 | |
| 1.80p | +0.025 | +1.4% | 1.775p | 1.90p | 1.70p | 876,765 | |
| 1.775p | -0.04 | -2.2% | 1.70p | 1.85p | 1.70p | 1,010,392 | |
| 1.815p | +0.055 | +3.1% | 1.75p | 1.815p | 1.651p | 1,948,803 | |
| 1.76p | +0.01 | +0.6% | 1.75p | 1.79p | 1.70p | 4,703,337 | |
| 1.75p | -0.07 | -3.8% | 1.75p | 1.90p | 1.70p | 5,111,674 | |
| 1.82p | -0.28 | -13.3% | 2.00p | 2.05p | 1.70p | 13,726,239 | |
| 2.10p | +0.10 | +5.0% | 2.00p | 2.10p | 1.881p | 20,332,187 | |
| 2.00p | 0.00 | 0.0% | 2.00p | 2.10p | 1.90p | 579,253 | |
| 2.00p | +0.025 | +1.3% | 1.975p | 2.10p | 1.922p | 1,919,887 | |
| 1.975p | 0.00 | 0.0% | 1.975p | 2.00p | 1.95p | 2,507,630 | |
| 1.975p | -0.015 | -0.8% | 1.975p | 2.04p | 1.88p | 932,792 | |
| 1.99p | +0.065 | +3.4% | 1.925p | 2.00p | 1.90p | 1,868,010 | |
| 1.925p | +0.05 | +2.7% | 1.875p | 1.99p | 1.831p | 1,814,406 | |
| 1.875p | -0.05 | -2.6% | 1.925p | 1.944p | 1.816p | 1,642,496 | |
| 1.925p | -0.025 | -1.3% | 1.95p | 1.968p | 1.855p | 2,077,451 | |
| 1.95p | -0.08 | -3.9% | 1.975p | 2.00p | 1.86p | 6,070,981 | |
| 2.03p | +0.08 | +4.1% | 1.975p | 2.05p | 1.90p | 4,972,603 | |
| 1.95p | -0.075 | -3.7% | 2.025p | 2.05p | 1.865p | 6,609,426 | |
| 2.025p | -0.15 | -6.9% | 2.175p | 2.25p | 2.00p | 2,569,676 | |
| 2.175p | -0.025 | -1.1% | 2.20p | 2.40p | 2.10p | 3,538,514 | |
| 2.20p | +0.02 | +0.9% | 2.25p | 2.38p | 2.10p | 4,116,690 | |
| 2.18p | -0.02 | -0.9% | 2.20p | 2.30p | 2.10p | 629,431 | |
| 2.20p | -0.05 | -2.2% | 2.25p | 2.335p | 2.10p | 816,879 | |
| 2.25p | -0.15 | -6.2% | 2.45p | 2.47p | 2.10p | 2,869,735 | |
| 2.40p | -0.06 | -2.4% | 2.85p | 2.94p | 2.40p | 12,036,956 | |
| 2.46p | +0.285 | +13.1% | 2.20p | 2.50p | 2.10p | 3,547,104 | |
| 2.175p | +0.025 | +1.2% | 2.15p | 2.30p | 2.10p | 2,577,553 | |
| 2.15p | +0.05 | +2.4% | 2.05p | 2.20p | 2.00p | 1,568,340 | |
| 2.10p | +0.05 | +2.4% | 2.05p | 2.10p | 2.00p | 944,166 | |
| 2.05p | 0.00 | 0.0% | 2.05p | 2.14p | 2.00p | 552,620 | |
| 2.05p | -0.05 | -2.4% | 2.05p | 2.10p | 2.00p | 384,497 | |
| 2.10p | +0.10 | +5.0% | 2.00p | 2.10p | 1.90p | 989,850 | |
| 2.00p | 0.00 | 0.0% | 2.00p | 2.10p | 1.926p | 178,380 | |
| 2.00p | +0.025 | +1.3% | 1.975p | 2.095p | 1.911p | 1,422,075 | |
| 1.975p | +0.025 | +1.3% | 1.95p | 2.05p | 1.90p | 344,799 | |
| 1.95p | +0.025 | +1.3% | 1.925p | 2.04p | 1.90p | 789,758 | |
| 1.925p | 0.00 | 0.0% | 1.925p | 2.04p | 1.85p | 220,851 |
- Ticker
- LSE:GENF
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- LSE
- Currency
- GBX
What changed lately
Latest news release · Oct 30, 2026
Total Voting Rights
Latest deck · July 2026
Investor Presentation (July 2026)
Investor deck · 20 slides
Latest news
Total Voting Rights
Oct 30, 2026
Closed 1.83p (0.0%) on Oct 30, 2026
Corporate Update
Oct 9, 2026
Closed 1.78p (-2.2%) on Oct 9, 2026
Genflow Biosciences PLC Announces Presentation of Interim Results
Oct 5, 2026
Closed 1.82p (-13.3%) on Oct 5, 2026
Presentation of Interim Results
Oct 5, 2026
Closed 1.82p (-13.3%) on Oct 5, 2026
Genflow Biosciences PLC Announces Half-year Financial Report
Sep 29, 2026
Closed 1.98p (0.0%) on Sep 29, 2026
Genflow Biosciences PLC Announces Primary Endpoint in SLAB Clinical Trial Met
Sep 8, 2026
Closed 2.40p (-2.4%) on Sep 8, 2026
Genflow Biosciences PLC Announces Appointment of Investor Relations Adviser
Sep 7, 2026
Closed 2.46p (+13.1%) on Sep 7, 2026
Genflow Biosciences PLC Announces Patent Update
Aug 3, 2026
Closed 1.95p (+16.4%) on Aug 3, 2026
Genflow Biosciences PLC Announces Mid-Year Operational and Corporate Summary
Jul 13, 2026
Closed 1.93p (-1.3%) on Jul 13, 2026
Genflow Biosciences PLC Announces Result of AGM
Jun 29, 2026
Closed 2.25p (+2.3%) on Jun 29, 2026
Genflow Biosciences PLC on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 34 in the last 12 months · 120 in all · newest Oct 30, 2026 · oldest 2022
- Decks
- 3 decks · latest July 2026
Where Genflow Biosciences PLC is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| LSE:GENF · Home listing · This page | LSE | United Kingdom | GBX |
| OTC:GENFF | OTC | United States | USD |
| Frankfurt:WQ5 | Frankfurt | Germany | EUR |
| Lang & Schwarz:A3DCSM | Lang & Schwarz | Germany | EUR |
| LS Exchange:A3DCSM | LS Exchange | Germany | EUR |
| Stuttgart:WQ5 | Stuttgart | Germany | EUR |
Valuation
Price/book 48.5× against a median of 1.9×: the highest of 7 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- £8.58M GBP
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 48.5×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Genflow Biosciences PLC · LSE:GENF | US$12.06M | US$11.23M | n/a | n/a | n/a | 48.5× | n/a | 0.0× | n/a |
| Allarity Therapeutics, Inc. · NASDAQ:ALLR | US$12.56M | US$21.48M | n/a | 61.4× | n/a | n/a | n/a | n/a | 1.40 |
| Lobe Sciences Ltd · CSE:LOBE | US$12.52M | US$8.89M | n/a | n/a | n/a | 9.5× | n/a | 0.0× | 0.31 |
| Biophytis SA · EURONEXT:ALBPS | US$12.47M | US$19.44M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| MIRA Pharmaceuticals, Inc. · NASDAQ:MIRA | US$12.23M | US$5.26M | n/a | n/a | n/a | 1.8× | n/a | 0.0× | 1.48 |
| BioCardia, Inc. · NASDAQ:BCDA | US$11.88M | US$10.22M | n/a | n/a | n/a | 14.2× | n/a | 0.7× | 0.42 |
| Xintela AB · OMXSTO:XINT | US$11.88M | US$11.81M | n/a | 39.8× | n/a | n/a | n/a | n/a | n/a |
| Pluri Inc. · NASDAQ:PLUR | US$11.85M | US$38.65M | n/a | 26.5× | n/a | n/a | n/a | n/a | 0.53 |
| Synlogic Inc · OTC:SYBX | US$11.76M | US$201,442 | n/a | n/a | n/a | 1.2× | n/a | 0.0× | 0.50 |
| Imugene Ltd · ASX:IMU | US$11.74M | US$14.16M | n/a | n/a | n/a | 2.0× | n/a | 0.7× | n/a |
| Radiopharm Theranostics Limited · ASX:RAD | US$11.59M | US$8.85M | n/a | 4.8× | n/a | 0.7× | n/a | 0.0× | n/a |
| Median of the others | US$11.88M | US$11.02M | 33.2× | 1.9× | 0.0× | 0.52 |
Team and board
Officers
| Officer | Role |
|---|---|
| Eric Leire | CHIEF EXECUTIVE OFFICER |
| Eric Laub | Investor Relations |
| Guy Charles Fanneau de la Horie | NON-EXECUTIVE DIRECTOR - Head of Audit Committee |
| Tamara Joseph | Non-Executive Director - Head of Governance Committee |
| Yassine Bendiabdallah | NON-EXECUTIVE DIRECTOR - Head of Remuneration Committee |
Board
| Director | Role |
|---|---|
| Gad Berdugo | Chairperson |
| Guy Charles Fanneau de la Horie | NON-EXECUTIVE DIRECTOR - Head of Audit Committee |
| Tamara Joseph | Non-Executive Director - Head of Governance Committee |
| Yassine Bendiabdallah | NON-EXECUTIVE DIRECTOR - Head of Remuneration Committee |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q2 2025 | Sep 30, 2025 | −8.1% |
| Q1 2025 | Apr 30, 2025 | −2.4% |
| Q2 2024 | Sep 30, 2024 | −4.7% |
| Q1 2023 | Apr 24, 2023 | +25.0% |
| Q2 2022 | Sep 30, 2022 | −1.9% |
| Q1 2022 | Apr 25, 2022 | −5.3% |
| Q4 2021 | Jan 17, 2022 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (July 2026) | Investor deck | 20 slides | July 2026 |
| Investor Presentation (March 2026) | Investor deck | 20 slides | March 2026 |
| Investor Presentation (March 2024) | Investor deck | 18 slides | March 2024 |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Private placement of new ordinary shares (and/or warrants) Announced: private placement Use of proceeds: Moving MASH program to IND-enabling stage, animal health dog trial payment and licensing, glaucoma proof of concept studies, and EU and US patent work | Feb 11, 2026 | |
| Private placement of new ordinary shares with warrants Cancelled: £340,000 · £0.85 a share · Warrants at £1.2 for 24 months Buyers: Eric Leire (40,000,000 new ordinary shares at 0.85 pence, to be directed to an institution for sale to a purchaser) Insiders: Subscription by CEO and director Eric Leire, who will direct the shares to an institution for immediate sale to a purchaser Use of proceeds: Continue the dog study while awaiting the Wallonia region grant; working capital | Oct 9, 2025 | US$456,978 |
| Private placement of new ordinary shares with warrants Closed: £440,000 raised · GBX 1.1 a share · Warrants at GBX 1.2 for 24 months Buyers: Eric Leire (4,545,454 New Ordinary Shares); consortium of existing shareholders (35,454,546 New Ordinary Shares) Insiders: CEO and director Eric Leire subscribed for the 40,000,000 shares, directing 35,454,546 to existing shareholders and keeping 4,545,454 | Oct 9, 2025 | US$586,174 |
| Private placement of new ordinary shares with warrants Closed: £500,000 raised · GBX 0.8 a share · Warrants at GBX 1.5 for 36 months Buyers: Eric Leire (subscription for 62,500,000 New Ordinary Shares, to be directed to an institution and sold to a purchaser) Insiders: Subscription by CEO and director Eric Leire, who directs the shares to an institution that sells them to a purchaser at the same price Use of proceeds: Advance a proof-of-concept trial of its therapeutic candidate in aged dogs | May 9, 2025 | US$665,147 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in GBP
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 169.9K | 0 | 0 | |
| Cost of revenue | 1.09K | 1.20K | 1.03K | 130 | ||
| Gross profit | 585.6K | 320.5K | -1.03K | -130 | ||
| Research and development | 1.11M | 1.15M | 960.3K | 724.5K | 86.0K | 93.9K |
| Selling, general and administrative | 497.6K | 1.81M | 1.80M | 499.3K | 527.7K | 649.9K |
| Operating income | -1.42M | -1.59M | -2.03M | -1.82M | -988.1K | -649.9K |
| Depreciation and amortization | 1.09K | 1.18K | 1.03K | 129 | 236.6K | 649.9K |
| EBITDA | -1.42M | -1.59M | -2.03M | -1.82M | -751.5K | 0 |
| Interest expense | 0 | 0 | 0 | 382 | 99 | |
| Income before tax | -1.42M | -1.59M | -1.86M | -1.34M | -988.2K | -651.0K |
| Income tax | 0 | 0 | 0 | 0 | 99 | -1.09K |
| Net income | -1.42M | -1.59M | -1.86M | -1.34M | -988.3K | -651.0K |
| Earnings per share, basic | -0.33 | -0.48 | -0.01 | -0.00 | -0.00 | -0.82 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2021 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 111.8K | 278.7K | 684.0K | 2.36M | 224.0K | 254.2K |
| Receivables | 339.5K | 105.2K | 384.3K | 258.9K | 52.5K | 19.5K |
| Current assets | 451.3K | 383.8K | 1.07M | 2.62M | 276.6K | 283.8K |
| Property, plant and equipment | 1.07K | 2.07K | 3.39K | 2.35K | ||
| Total assets | 452.4K | 385.9K | 1.07M | 2.62M | 276.6K | 283.8K |
| Accounts payable | 1.00M | 788.9K | 572.0K | 251.0K | 37.7K | 52.8K |
| Current liabilities | 1.00M | 788.9K | 572.0K | 251.0K | 221.4K | 64.8K |
| Total liabilities | 1.00M | 788.9K | 572.0K | 251.0K | 221.4K | 64.8K |
| Shareholders' equity | -550.8K | -403.0K | 499.7K | 2.37M | 55.1K | 219.0K |
| Shares outstanding | 426.7M | 334.5M | 292.5M | 292.5M | 292.5M | 796.1K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2021 |
|---|---|---|---|---|---|---|
| Cash from operations | -1.44M | -1.08M | -1.66M | -1.37M | -747.4K | -439.5K |
| Capital spending | -5 | 0 | -2.44K | -2.48K | 0 | 0 |
| Free cash flow | -1.44M | -1.08M | -1.66M | -1.37M | -747.4K | -439.5K |
| Cash from investing | 0 | 0 | -2.44K | -2.48K | 198.5K | 216.5K |
| Cash from financing | 1.31M | 656.6K | 0 | 3.50M | 783.7K | 1.96M |
| Change in cash | -127.9K | -425.6K | -1.66M | 2.13M | 234.8K | 1.74M |
Cap table
Built by 6ix from Genflow Biosciences PLC’s releases · as of Feb 11, 2026
- Common shares
- 594,534,781
- Fully diluted
- 594,534,781
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 594,534,781 |
Warrants and options
| Lot |
|---|
| Warrants · 1.20 GBX · expire about Oct 2027 |
| Warrants · 1.50 GBX · expire about May 2028 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 594,534,781 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Eric Laub | Investor Relations · Since at least Sep 29, 2026 |
| Eric Leire | CHIEF EXECUTIVE OFFICER · Since at least Oct 30, 2026 |
| Gad Berdugo | Chairperson · Since at least Sep 29, 2026 |
| Guy Charles Fanneau de la Horie | NON-EXECUTIVE DIRECTOR - Head of Audit Committee · Since at least Jun 29, 2026 |
| Tamara Joseph | Non-Executive Director - Head of Governance Committee · Since at least Jul 13, 2026 |
| Yassine Bendiabdallah | NON-EXECUTIVE DIRECTOR - Head of Remuneration Committee · Since at least Jun 29, 2026 |
Log in to ask 6ix AI your own questions about Genflow Biosciences PLC.